Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Expression of STAT3 in Prostate Cancer Metastases

Don-Doncow, Nicholas LU ; Marginean, Felicia LU orcid ; Coleman, Ilsa ; Nelson, Peter S. ; Ehrnström, Roy LU ; Krzyzanowska, Agnieszka LU ; Morrissey, Colm ; Hellsten, Rebecka LU and Bjartell, Anders LU (2017) In European Urology 71(3). p.313-316
Abstract

STAT3 and its upstream activator IL6R have been implicated in the progression of prostate cancer and are possible future therapeutic targets. We analyzed 223 metastatic samples from rapid autopsies of 71 patients who had died of castration-resistant prostate cancer (CRPC) to study protein and gene expression of pSTAT3 and IL6R. Immunohistochemical analysis revealed that 95% of metastases were positive for pSTAT3 and IL6R, with varying expression levels. Bone metastases showed significantly higher expression of both pSTAT3 and IL6R in comparison to lymph node and visceral metastases. STAT3 mRNA levels were significantly higher in bone than in lymph node and visceral metastases, whereas no significant difference in IL6R mRNA expression... (More)

STAT3 and its upstream activator IL6R have been implicated in the progression of prostate cancer and are possible future therapeutic targets. We analyzed 223 metastatic samples from rapid autopsies of 71 patients who had died of castration-resistant prostate cancer (CRPC) to study protein and gene expression of pSTAT3 and IL6R. Immunohistochemical analysis revealed that 95% of metastases were positive for pSTAT3 and IL6R, with varying expression levels. Bone metastases showed significantly higher expression of both pSTAT3 and IL6R in comparison to lymph node and visceral metastases. STAT3 mRNA levels were significantly higher in bone than in lymph node and visceral metastases, whereas no significant difference in IL6R mRNA expression was observed. Our study strongly supports the suggested view of targeting STAT3 as a therapeutic option in patients with metastatic CRPC. Patient summary We studied the levels of two proteins (pSTAT3 and IL6R) in metastases from patients who died from castration-resistant prostate cancer. We found high levels of pSTAT3and IL6R in bone metastases, suggesting that these proteins could be used as targets for new anticancer drugs.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Castration-resistant, Metastases, Prostate cancer, STAT3, Tissue microarray
in
European Urology
volume
71
issue
3
pages
4 pages
publisher
Elsevier
external identifiers
  • pmid:27344294
  • wos:000396333700006
  • scopus:84998843866
ISSN
0302-2838
DOI
10.1016/j.eururo.2016.06.018
language
English
LU publication?
yes
id
90216b63-cc44-4918-a44f-01432f4d9eb0
date added to LUP
2017-02-03 08:13:26
date last changed
2025-03-09 01:10:34
@article{90216b63-cc44-4918-a44f-01432f4d9eb0,
  abstract     = {{<p>STAT3 and its upstream activator IL6R have been implicated in the progression of prostate cancer and are possible future therapeutic targets. We analyzed 223 metastatic samples from rapid autopsies of 71 patients who had died of castration-resistant prostate cancer (CRPC) to study protein and gene expression of pSTAT3 and IL6R. Immunohistochemical analysis revealed that 95% of metastases were positive for pSTAT3 and IL6R, with varying expression levels. Bone metastases showed significantly higher expression of both pSTAT3 and IL6R in comparison to lymph node and visceral metastases. STAT3 mRNA levels were significantly higher in bone than in lymph node and visceral metastases, whereas no significant difference in IL6R mRNA expression was observed. Our study strongly supports the suggested view of targeting STAT3 as a therapeutic option in patients with metastatic CRPC. Patient summary We studied the levels of two proteins (pSTAT3 and IL6R) in metastases from patients who died from castration-resistant prostate cancer. We found high levels of pSTAT3and IL6R in bone metastases, suggesting that these proteins could be used as targets for new anticancer drugs.</p>}},
  author       = {{Don-Doncow, Nicholas and Marginean, Felicia and Coleman, Ilsa and Nelson, Peter S. and Ehrnström, Roy and Krzyzanowska, Agnieszka and Morrissey, Colm and Hellsten, Rebecka and Bjartell, Anders}},
  issn         = {{0302-2838}},
  keywords     = {{Castration-resistant; Metastases; Prostate cancer; STAT3; Tissue microarray}},
  language     = {{eng}},
  month        = {{03}},
  number       = {{3}},
  pages        = {{313--316}},
  publisher    = {{Elsevier}},
  series       = {{European Urology}},
  title        = {{Expression of STAT3 in Prostate Cancer Metastases}},
  url          = {{https://lup.lub.lu.se/search/files/31063393/20911680_.pdf}},
  doi          = {{10.1016/j.eururo.2016.06.018}},
  volume       = {{71}},
  year         = {{2017}},
}